Rabbit anti-Human GBA Polyclonal Antibody | anti-GBA antibody

GBA Polyclonal Antibody

Cat. Num. AAA9127930

• Gene Names: GBA; GCB; GBA1; GLUC
• Reactivity: Human
• Applications: Western Blot
• Purity: Affinity Purification
• Synonyms: GBA; Polyclonal Antibody; GBA Polyclonal Antibody; GBA;GBA1;GCB;GLUC; anti-GBA antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Purity/Purification: Affinity Purification
• Form/Format: Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
• Sequence Length: 487

• Applicable Applications for anti-GBA antibody: Western Blot (WB)
• Application Notes: WB 1:500 - 1:2000
• Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 40-250 of human Glucosylceramidase beta (Glucosylceramidase beta (GBA)) (NP_000148.2).
• Preparation and Storage: Store at -20 degree C. Avoid freeze / thaw cycles.

Western Blot (WB)

(Western blot analysis of extracts of MCF-7 cells, using GBA antibody at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (MBS128200) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit.Exposure time: 90s.)

Related Product Information for anti-GBA antibody

This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants.

NCBI and Uniprot Product Information

• NCBI GI #: 54607043
• NCBI GeneID: 2629
• NCBI Accession #: NP_000148.2
• NCBI GenBank Nucleotide #: NM_000157.3
• UniProt Accession #: P04062; Q16545; Q4VX22; Q6I9R6; Q9UMJ8; A8K796; B7Z5G2; B7Z6S1; J3KQG4; J3KQK9
• Molecular Weight: Observed MW: 60kDa; Calculated MW: 29kDa/50kDa/54kDa/57kDa/59kDa
• NCBI Official Full Name: glucosylceramidase isoform 1
• NCBI Official Synonym Full Names: glucosidase, beta, acid
• NCBI Official Symbol: GBA
• NCBI Official Synonym Symbols: GCB; GBA1; GLUC
• NCBI Protein Information: glucosylceramidase
• UniProt Protein Name: Glucosylceramidase
• Protein Family: Glucosylceramidase
• UniProt Gene Name: GBA
• UniProt Synonym Gene Names: GC; GLUC; Beta-GC
• UniProt Entry Name: GLCM_HUMAN

NCBI Description

This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2010]

Uniprot Description

GBA: Defects in GBA are the cause of Gaucher disease (GD); also known as glucocerebrosidase deficiency. GD is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Different clinical forms are recognized depending on the presence (neuronopathic forms) or absence of central nervous system involvement, severity and age of onset. Defects in GBA are the cause of Gaucher disease type 1 (GD1); also known as adult non-neuronopathic Gaucher disease. GD1 is characterized by hepatosplenomegaly with consequent anemia and thrombopenia, and bone involvement. The central nervous system is not involved. Defects in GBA are the cause of Gaucher disease type 2 (GD2); also known as acute neuronopathic Gaucher disease. GD2 is the most severe form and is universally progressive and fatal. It manifests soon after birth, with death generally occurring before patients reach two years of age. Defects in GBA are the cause of Gaucher disease type 3 (GD3); also known as subacute neuronopathic Gaucher disease. GD3 has central nervous manifestations. Defects in GBA are the cause of Gaucher disease type 3C (GD3C); also known as pseudo-Gaucher disease or Gaucher-like disease. Defects in GBA are the cause of Gaucher disease perinatal lethal (GDPL). It is a distinct form of Gaucher disease type 2, characterized by fetal onset. Hydrops fetalis, in utero fetal death and neonatal distress are prominent features. When hydrops is absent, neurologic involvement begins in the first week and leads to death within 3 months. Hepatosplenomegaly is a major sign, and is associated with ichthyosis, arthrogryposis, and facial dysmorphism. Perinatal lethal Gaucher disease is associated with non-immune hydrops fetalis, a generalized edema of the fetus with fluid accumulation in the body cavities due to non-immune causes. Non-immune hydrops fetalis is not a diagnosis in itself but a symptom, a feature of many genetic disorders, and the end-stage of a wide variety of disorders. Defects in GBA contribute to susceptibility to Parkinson disease (PARK). A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. Belongs to the glycosyl hydrolase 30 family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: EC 3.2.1.45; Lipid Metabolism - sphingolipid; Glycan Metabolism - other glycan degradation; Hydrolase

Chromosomal Location of Human Ortholog: 1q21

Cellular Component: lysosomal lumen; lysosomal membrane

Molecular Function: protein binding; receptor binding; glucosylceramidase activity

Biological Process: glucosylceramide catabolic process; negative regulation of MAP kinase activity; sphingolipid metabolic process; skin morphogenesis; response to glucocorticoid stimulus; response to testosterone stimulus; positive regulation of protein amino acid dephosphorylation; regulation of water loss via skin; response to estrogen stimulus; negative regulation of inflammatory response; carbohydrate metabolic process; sphingosine biosynthetic process; negative regulation of interleukin-6 production; ceramide biosynthetic process; glycosphingolipid metabolic process; response to pH

Disease: Gaucher Disease, Type Ii; Dementia, Lewy Body; Parkinson Disease, Late-onset; Gaucher Disease, Type Iiic; Gaucher Disease, Perinatal Lethal; Gaucher Disease, Type Iii; Gaucher Disease, Type I